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Abstract
Genome integrity is constantly monitored by sophisticated cellular networks, 
collectively termed as the DNA damage response (DDR). The DDR is a signaling 
network that includes cell cycle checkpoints and DNA repair and damage toler-
ance pathways. Failure of the DDR or associated events causes various diseases, 
including cancer. DDR is primarily mediated by phosphatidylinositol-3-kinase-like 
protein kinase (PIKKs) family members ataxia-telangiectasia mutated (ATM) and 
ataxia telangiectasia and Rad3-related protein (ATR). However, one of the many 
unanswered questions regarding these signal-transduction pathways is: how does 
the cell turn the DDR signals on? There was no conclusive demonstration of the 
involvement of a specific sensory kinase in DDR signals until our recent research on 
the DCLK1 role in regulating ATM after genotoxic injury. Currently, various studies 
are demonstrating the importance of DCLK1 in DNA damage response. Here, we 
discuss the novel insights into the role of DCLK1 in DNA damage response.
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1. Introduction
DNA damage exists in all cellular organisms, and DNA, the genetic material 
in each living cell is the fundamental unit of life and its integrity and stability are 
essential to life [1]. However, DNA is not passive; rather, it is a chemical unit subject 
to be attacked from a range of endogenous and environmental damaging agents. The 
endogenous damages are the damage caused by reactive oxygen species or metabolic 
byproducts, and DNA metabolization; exogenous damages are caused by external 
agents, like radiations, toxins, chemicals, and microorganisms [2]. In response to 
the DNA damage, cells rapidly recruit a sophisticated network which is called DNA 
damage-response (DDR) systems. DDR systems include DNA repair mechanisms, 
damage tolerance processes, and cell-cycle checkpoint pathways [3]. Failure of DDR 
causes genomic instability which results in various diseases including immune defi-
ciency, neurological degeneration, premature aging, and severe cancer susceptibility 
[2, 4]. Indeed, great progress has been made towards understanding the mecha-
nisms of DDR in homeostasis, carcinogenesis and cancer advancement but much 
remains to delineate how the DDR network systems are regulated. Furthermore, 
how the DDR network is formed and how it is fine-tuned by upstream and down-
stream mediators or signaling pathways that support the homeostasis or disease 
progression required to understand. While the rapid activation of DDR against the 
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DNA damage is expected, it is unclear how and who activates or gives the instruc-
tion to DDR network systems? Gaining knowledge about DDR and its regulators 
will not only enhance our understanding of DDR functions but will undoubtedly 
giving us opportunities to better manage human diseases. Although, very few 
studies reported that protein kinases and DNA adaptor molecules or DNA regulators 
may influence or send signals to DDR after DNA gets damaged [5, 6]. DCLK1 is a 
member of the protein kinase superfamily and the doublecortin family, that belongs 
to the group of microtubule-associated proteins [7]. Our novel findings that DCLK1 
regulate DNA damage response and cell survival following genotoxic injury opens 
many windows of how DDR is regulated [8]. In this chapter we will highlight the 
functional role of DCLK1 in injury, DDR and cell survival, which will lead us to a 
better understanding of DCLK1 expression in helping genomic stability in normal 
and neoplastic cells.
2. DNA damage, DNA damage response, and DNA repair
DNA is the source of genetic information in all living cells, its integrity and 
fidelity are essential to life. Because DNA is not passive, it is a chemical entity 
subject to be assaulted from various reactive agents, causing DNA damage [9]. 
DNA damage can be subdivided into two types: (1) endogenous damage caused by 
reactive oxygen species (ROS) that are derived from metabolic byproducts and (2) 
exogenous damage caused by radiation (UV, X-ray, gamma), hydrolysis, plant tox-
ins, and viruses, chemical toxins [9, 10]. Most of the DNA damage can be repaired 
by the host systems called the DNA damage response (DDR) and DNA repair 
systems. Such systems also face failure and not 100% efficient, which resulted 
in either cell death or cell survival with un-repaired DNA causing mutation and 
eventually cancer [11]. In some cases, the un-repaired DNA damage accumulates in 
non-replicating cells, such as neurons or myocytes of adult mammals, and can cause 
aging [12]. The DDR is a sophisticated cellular network, which constantly monitors 
the integrity of the genome, in response to DNA damage [13]. Once the DDR gets 
activated it rapidly recruit downstream protein sensors and adaptors establishing 
the sensing, activating repair, tolerating damage and apoptosis (Figure 1). DDR is 
primarily mediated by phosphatidylinositol-3-kinase-like protein kinase (PIKKs) 
family members, ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia 
and Rad3-related protein (ATR) and DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs) [13, 14]. The ATM pathway for homologous recombination 
(HR) repair is activated after a double-stranded break. The ATR pathway for 
nonhomologous end-joining (NHEJ) is associated with single-stranded DNA and 
stalled DNA replication forks. ATM pathway is a higher-fidelity repair pathway 
than the ATR. For lesions repaired by the HR, double-strand breaks (DSBs) are 
detected and processed by the MRE11–RAD50–NBS1 (MRN) complex [15, 16]. For 
lesions repaired by the NHEJ, DNA breaks are detected and the process by the ATR 
interacting protein (ATRIP) complex. ATM and ATR transduce the most upstream 
DDR signal by phosphorylating the checkpoint kinases CHK1/CHK2 and the tumor 
suppressor protein p53, which resulted in cell cycle arrest to allow time for DNA 
repair. The main function of DNA-PK activated under the ATM/ATR pathway is to 
induce cell cycle arrest and DNA repair [17]. DNA repair is a vital cellular process 
required for the maintenance of genomic integrity and fidelity [18]. Living cells 
employ several DNA repair pathways for distinct types of DNA damage. There are 
five major DNA repair pathways: (1) mismatch repair (MMR), (2) nucleotide exci-
sion repair (NER), (3) base excision repair (BER), (4) homologous recombinational 
repair (HR), and (5) non-homologous end joining (NHEJ) [19, 20]. MMR’s primary 
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function is to remove base mismatches and small insertion and deletion loops 
which is introduced during replication. The NER pathway is a multistep process 
that serves to repair a variety of DNA damage, including DNA lesions caused by 
UV radiation, toxic chemicals, or chemotherapeutic drugs that form huge DNA 
adducts. BER primarily repairs non-bulky lesions produced by alkylation, oxida-
tion or deamination of bases. The BER pathway deals with base damage, the most 
common insult to cellular DNA. DSBs can be repaired by either HR or NHEJ. HR 
uses a homologous DNA template and is highly accurate, whereas NHEJ rejoins the 
broken ends without using a template and is often accompanied by loss of some 
nucleotides. Direct reversal of DNA damage is one repair mechanism used to restore 
damaged DNA without using excision, resynthesis, and ligation [21, 22].
3. DCLK1
The human doublecortin (DCX) gene family comprises members that share 
the tubulin-binding domain and known to have limited functions in microtubule-
associated regulation and neuronal-regulation [23]. One of the best known 
and most interesting members of this DCX family is doublecortin-like kinase 1 
(DCLK1 also known as DCAMKL1), a gene encoding for a protein that is 70% iden-
tical to doublecortin in the microtubule-binding N-terminal domain. However, 
unlike doublecortin, the DCKL1 gene also encodes for a serine–threonine kinase 
C-terminal domain that is similar to Ca2+/calmodulin-dependent protein kinase II 
but lacks a canonical calmodulin-binding site [24, 25]. DCLK1 gene also encodes 
Figure 1. 
DNA damage, DNA damage response, and repair. Graphical illustration demonstrating the DNA damage 
caused by different sources and the cellular response to DNA damage.
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for a serine/proline-rich domain in between the doublecortin and the protein 
kinase domains, which mediates multiple protein–protein interactions. In humans, 
DCLK1 consists of four primary isoforms with a shared kinase domain-driven from 
two promoter regions termed α and β (Figure 2) [26–28]. The α-promoter drives 
the expression of isoforms termed α-long (isoform 2) and α-short (isoform 1) 
which contain an N-terminal microtubule-binding region with high homology to 
DCX. Importantly, the α-promoter isoforms are specifically expressed in the DCLK1+ 
tuft cells that eventually give rise to tumor stem cells following relevant mutagenesis 
in the colon and pancreatic cancer [29–31]. The β-promoter drives the expression 
of two isoforms termed β-long (isoform 4) and β-short (isoform 3) that can be 
used to predict survival in colon cancer [32]. Although these isoforms likely play a 
significant role in tumorigenesis through their kinase activity, there is no evidence 
that they are functionally involved in the regulation of DDR, until our first report 
to demonstrate its direct interaction with ATM.
4. DCLK1 and DDR following injury and inflammation
Cell survival after severe injury requires highly coordinated complex interplay 
between the diverse molecular signaling responses to repair the injury [15, 33]. 
We discussed three fundamental standards about the critical role of DCLK1 in 
intestinal epithelial cell survival after severe genotoxic injury: (1) how intestinal 
epithelial cells respond to severe DNA damage because intestinal epithelial cells 
are the most affected cells after bone marrow during radiotherapy or accidental or 
incidental radiation exposure [34] and (2) how DCLK1 a kinase protein expression 
Figure 2. 
Human DCLK1-isoforms. Graphical illustration demonstrating the length of each isoform and shared 
protein kinase domain between DCLK1 isoforms referenced in UniProt; www.uniprot.org/uniprot/O15075. 
DCX1 = Doublecortin1; DCX2 = Doublecortin2; and P/S = pro/Ser rich domain and a protein kinase domain.
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play key role in injury response, because DCLK1 expressing cells survive high 
dose radiation and DSS-induced inflammation [29]. It is reported that the dele-
tion of DCLK1 (VillinCre;DCLK1f/f mice) in the intestinal epithelial cells does not 
confer a significant deleterious phenotype in adult mice, compared with their 
wild-type littermates [35]. However, after 24 h of 12 Gy total body irradiation 
(TBI), none of the intestinal epithelial-specific DCLK1 knockout mice survived 
longer than 5 days [35]. The best-known primary defense mechanism against the 
genotoxic injury-induced DNA damage is the DDR, which repairs the damaged 
DNA and increased the survival of intestinal epithelial cells [36]. Indeed stud-
ies demonstrated that deficient DDR has been suggested to increase intestinal 
epithelial death and loss of survival [37]. During the early event of DNA damage, 
the ATM-H2AX axis gets activated, generating gamma-H2AX and other adaptors, 
providing a stage for efficient homologous recombinant repair [38]. Recently, ATM 
knockout or loss of Rad50 and Mre11 was reported to increase intestinal injury and 
lethality [39, 40]. But how these DDR signaling pathways were regulated following 
radiation injury is not well known. Chandrakesan et al. reported that the absence 
of DCLK1 expression in the intestinal epithelial cells abrogated the activation and 
expression of ATM, gamma-H2AX, and downstream adopter proteins BRCA1, 
Rad50, and MRE11 in the intestinal epithelial cells 24 h post-TBI [8]. Furthermore, 
it is reported that this reduction persisted up to 3.5 days post-TBI. It is suggested 
that there is a profound defect in intestinal DDR in DCLK1 knock-out mice, which 
Figure 3. 
DCLK1 and DDR. Graphical illustration demonstrating the regulatory role of DCLK1 in DDR following 
radiation injury.
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might contribute to defective epithelial survival and overall survival. Interestingly 
they established that phosphorylation of ATM which is critical for its activation is 
reduced in the intestinal epithelial cells of DCLK1 knock-out mice, under physi-
ological conditions, and discovered that DCLK1 can directly interact with ATM for 
its activation. ATM activation during and or after radiation injury directly depends 
on the ratio of DCLK1-ATM interaction [8]. Furthermore, DCLK1 knockdown 
and overexpression experiments with the YAMC cell line in vitro established that 
DCLK1 interaction is important for ATM activation. It is the first study to establish 
a direct link between DCLK1 and ATM mediated DDR, for the survival of cell in 
response to severe genotoxic injury (Figure 3).
5. DCLK1 in the regulation of DDR in cancers
A faulty DDR system can initiate cancer development [41]. Cancer cells with a 
DDR deficiency are profoundly dependent on remaining DDR [42, 43], for example 
in the case of ATM deficiency cancer cell relies on the ATR pathway. Therefore, 
DDR inhibition in cancers exploits these defects by inhibiting the remaining DDR 
system, and which in turn causes cancer cell death. Indeed the healthy cells are not 
vulnerable to DDR targeted therapies because normal cells can have higher expres-
sion of DDR only if they exposed to injury [44, 45]. Most cancer cells depend on 
their enhanced DDR activation for their survival, mainly activation of ATM and 
ATR pathways, and associated, CHK2, histone H2AX, and p53 [46, 47].
The present conventional radiotherapy and chemotherapies including platinum-
based therapies are used to kill cancer cells by inducing DNA damage. A huge 
problem that arises when using conventional therapies is the development of 
resistance by these cancer cells whose DDR repair the genomic instability, which 
causes conventional therapies to fail [48, 49]. Cancer cells as a short-term solution 
can bypass the DNA damage caused by chemotherapeutic agents by a mechanism 
known as translesion synthesis [50, 51]. Cancer cells with high DNA damage toler-
ance allow DNA replication to proceed in the presence of DNA damage include the 
convergence of adjacent replicons, re-priming of DNA synthesis downstream of 
lesions on the leading strand and discontinuous synthesis of Okazaki fragments on 
the lagging DNA strand [52, 53]. Given the fundamental role of DDR in the gain 
of chemo-resistance, the novel strategies of combination therapies including DDR 
targeted therapies will be effective [41]. Recent regulatory approval of olaparib 
(Lynparza), a poly (ADP ribose) polymerase (PARP) inhibitor, which inhibits 
PARP enzyme activity and forms severe DSBs [54]. In cancers, PARP inhibitor 
increases genomic instability that results in tumor cell death [55, 56]. Although, the 
pharmacological inhibitors of PARP have shown promising results in preclinical 
studies and in clinical trials, the gain of resistance in cancer cells to PARP inhibi-
tors, is inevitable [57]. However, the combination of PARP inhibitors with other 
DDR agents including ATR inhibitors, CHK1 inhibitors, ATM inhibitors, and 
DNA-PKs inhibitors, or with chemotherapeutic agents are novel strategies cur-
rently investigated to overcome resistance to PARP inhibitors [57] (Table 1—[58]). 
However, while the DDR targeted therapies are expected to cause DNA damage in 
tumor cells, it is unclear how these DDR networks are regulated in cancer cells? 
DDR regulators in cancers are reported recently, (1) MORC2 (MORC Family 
CW-Type Zinc Finger 2) is required for DNA damage-induced PAR production and 
PAR-dependent DNA repair signaling cascades and stimulates chromatin remodel-
ing [59, 60]. Inhibition of MORC2 in breast cancer cells impaired DDR and sensitize 
cancer cells to PARP inhibitors. (2) MYB is an oncogene that plays an important 
role in regulating DDR in ER+ breast cancers and inhibition of MYB induces DNA 
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ClinicalTrials.
gov identifier
Title Phase Drug target
NCT02797964 A Phase 1 Trial of SRA737 in Subjects with 
Advanced Cancer
I CHK1 inhibitor
NCT02797977 A Phase 1 Trial of SRA737 in Combination 
with Gemcitabine Plus Cisplatin or 
Gemcitabine Alone in Subjects with 
Advanced Cancer
I CHK1 inhibitor
Chemotherapy
NCT03057145 Combination Study of Prexasertib and 
Olaparib in Patients with Advanced Solid 
Tumors
I CHK1 inhibitor
PARP inhibitor
NCT02516813 Phase 1 Trial of MSC2490484A, an Inhibitor 
of a DNA-dependent Protein Kinase, in 
Combination with Radiotherapy
I DNA-PK inhibitor
Radiotherapy
NCT03308942 Phase 2, Multi-Arm Study of Niraparib 
Administered Alone and in Combination 
with PD-1 Inhibitor in Patients with Non-
Small Cell Lung Cancer
II PARP Inhibitor
PD-1 Inhibitor
NCT02660034 The Safety, Pharmacokinetics and Antitumor 
Activity of BGB-A317 in Combination with 
BGB-290 in Subjects with Advanced Solid 
Tumors
I PARP Inhibitor
PD-1 Inhibitor
NCT02264678 Ascending Doses of AZD6738 in 
Combination with Chemotherapy and/or 
Novel Anti Cancer Agents
I ATR Inhibitor
Chemotherapy
PDL-1 Inhibitor
NCT01844986 Olaparib Maintenance Monotherapy in 
Patients with BRCA Mutated Ovarian 
Cancer Following First Line Platinum Based 
Chemotherapy. (SOLO-1)
III PARP inhibitor
NCT02282020 Olaparib Treatment in Relapsed Germline 
Breast Cancer Susceptibility Gene (BRCA) 
Mutated Ovarian Cancer Patients Who Have 
Progressed at Least 6 Months After Last 
Platinum Treatment and Have Received at 
Least 2 Prior Platinum Treatments (SOLO3)
III PARP inhibitor
NCT02446704 Study of Olaparib and Temozolomide 
in Patients With Recurrent Small Cell 
Lung Cancer Following Failure of Prior 
Chemotherapy
I PARP inhibitor
NCT02789332 Assessing the Efficacy of Paclitaxel and 
Olaparib in Comparison to Paclitaxel/
Carboplatin Followed by Epirubicin/
Cyclophosphamide as Neoadjuvant 
Chemotherapy in Patients with HER2-
negative Early Breast Cancer and 
Homologous Recombination Deficiency 
(GeparOla)
II PARP inhibitor
Chemotherapy
NCT02264678 Ascending Doses of AZD6738 in 
Combination With Chemotherapy and/or 
Novel Anti Cancer Agents
Drug: administration of AZD6738 in 
combination with carboplatin
Drug: administration of AZD6738
Drug: administration of AZD6738 in 
combination with olaparib
Drug: administration of AZD6738 in 
combination with MEDI4736
I/II PARP inhibitor
Chemotherapy
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damage and tumor cell death [61]. (3) IKKα directly activates ATM via BRAF 
regulates DNA damage and inhibition of IKKα induces DNA damage associated cell 
death in colon cancer [62]. Although these signaling molecules are involved in the 
regulation of DDR in cancers, their mechanism and therapeutic efficiency are yet to 
develop.
DCLK1, a protein kinase is overexpressed in various tumor cancers [63–65]. 
DCLK1 plays a critical role in injury response for repair via regulating DDR [8]. 
However, recently the role of DCLK1 in the regulation of DDR in cancers has estab-
lished by many investigators [66–68]. In an in vitro mechanistic study, it is reported 
that DCLK1 caused chromatin instability, and chromatin rearrangement in colon, 
lung, and breast cancer cell lines, which drives the advancement of cancer cells for 
progression and this function is independent of its kinase activity [68]. In another 
study, it is reported that DCLK1 regulates the phosphorylation of CHK1 in pan-
creatic cancer cells. Inhibition of DCLK1 enhanced the sensitivity to gemcitabine 
treatment [67]. In a parallel study, it is shown that DCLK1 by regulating the phos-
phorylation of CHK1 enhances the sensitivity of 5-FU in colon cancer [69]. Taken 
together these reports suggest that DCLK1 plays a critical role in the regulation of 
DDR for cancer cell survival and progression. Novel therapies in the combination 
of targeting DCLK1 along with chemotherapeutic agents or targeting DCLK1 plus 
targeting an ATM or ATR with chemotherapeutic agents will be beneficial for the 
most effective treatment against cancers particularly the resistant cancers.
6. DCLK1 and radiation mitigators
Radiation therapy has been used for the treatment of a wide range of malig-
nancies, especially cancers. Radiation not only kills cancer cells, but it also kills/
affects normal healthy cells. Exposure of normal tissues to a substantial amount 
of radiation may cause both acute and chronic damage that can result in adverse 
effects for intended treatment [70, 71]. For example, radiation enteritis (RE) is an 
ClinicalTrials.
gov identifier
Title Phase Drug target
NCT00535353 AZD2281 and Irinotecan in Treating Patients 
with Locally Advanced or Metastatic 
Colorectal Cancer
I PARP inhibitor
Chemotherapy
NCT00678132 AZD2281 and Cisplatin Plus Gemcitabine to 
Treat Solid Tumor Cancers
I PARP inhibitor
Chemotherapy
NCT00515866 Study to Assess the Safety & Tolerability 
of a PARP Inhibitor in Combination with 
Gemcitabine in Pancreatic Cancer
I PARP inhibitor
Chemotherapy
NCT01460888 Radiotherapy & Olaparib in COmbination 
for Carcinoma of the Oesophagus 
(ROCOCO)
I PARP inhibitor
Radiotherapy
NCT02308072 Phase I Study of Olaparib Combined with 
Cisplatin-based Chemoradiotherapy to Treat 
Locally Advanced Head and Neck Cancer 
(ORCA-2)
I PARP inhibitor
Chemoradiotherapy
Selected clinical studies involving DDR inhibitors as a single agent or adjuvant therapy in combination with 
conventional chemotherapy or radiotherapy in cancer patients.
Table 1. 
Ongoing DDR inhibitor trials.
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intestinal inflammatory process that occurs in response to radiotherapy [72]. It 
is a major health concern characterized by abdominal pain, diarrhea, and rectal 
bleeding [73]. It can be complicated by translocation of gut bacteria into the 
circulation due to the loss of intestinal epithelial cells, disruption of intraepithelial 
tight junctions, and loss of regenerative ability resulting in severe impairment 
of gut function and even death. Relatively little is known about the mechanisms 
underlying the intestinal epithelial injury repair, cell survival and crypt regenera-
tion in RE. Besides the severe side effects resulted in gastrointestinal mucosal 
damage, ionizing radiation also impairs the bone marrow-derived hematopoietic 
cells and immune response, which causes a significant increase in morbidity and 
mortality [74]. Prevention and amelioration of radiation-induced adverse effects 
would improve the quality of life for patients and would help cancer curability by 
allowing more intense therapies [75].
There are three types of chemical/biological agents used to interfere with 
radiation effects. Agents used before or at the time of radiation treatment are called 
radioprotectors, whereas agents used post-treatment are called radiation mitigators, 
agents used to ameliorate established normal tissue toxicity are considered treat-
ment [76]. Currently, Amifostine is the only radioprotector in clinical use, and a 
few radiation mitigators been used [76]. DCLK1 can be a novel target for radiation 
mitigators for action, as it is mentioned above, deletion of DCLK1 within intestinal 
epithelial cells results in the premature death of mice following severe radiation 
injury, suggesting that DCLK1 is a major mediator of the crypt epithelial survival to 
severe genotoxic injury via a DDR-ATM mediated mechanism [8]. Recently, single-
cell analysis in the intestine has revealed that the DCLK1 expressing epithelial cells 
in the intestine is the primary source of Cox1 (Ptgs1) and Cox2 (Ptgs2) for PGE2 
synthesis [77]. PGE2 increases the survival of murine intestinal stem cells when 
given before photon radiation [78, 79]. It is reported that the treatment of dimethyl-
PGE2 to the intestinal epithelial cells increased the survival of the colonic epithelial 
cells by enhancing DCLK1 expression and reduced the DNA damage [8]. Qu et al. 
reported that Notch signaling in the intestinal epithelium prevents the death of 
epithelial cells expressing DCLK1 following radiation injury [80]. Also, dietary 
pectin has been demonstrated to increase intestinal crypt stem cell survival fol-
lowing radiation injury via a DCLK1 [81]. Kantara et al. have reported that a novel 
regenerative peptide TP508 can significantly increase survival and delay mortality 
by mitigating radiation-induced intestinal and colonic toxicity, and its mechanism 
of action via upregulating the expression of DCLK1 in the intestinal epithelial cells 
which are responsible for maintaining and regenerating intestinal crypts [82]. In 
summary, DCLK1 could be a potential radiation mitigator by regulating DDR to 
ameliorate radiation-induced adverse effects.
7. Conclusion
It is becoming clear that DCLK1 contributes to DNA damage response and 
repair via direct and indirect mechanisms that are distinct from its role as a stem 
cell marker. A long-standing question of how DDR is regulated in response to 
DNA damage is now getting a new clarity. Furthermore, (i) DCLK1 and ATM 
direct interaction for ATM activation following DSBs and (ii) radiation mitigators 
enhance the survival of cells following DSBs via a DCLK1 dependent mechanism, 
which expects that DCLK1 can be a potential target for radiation mitigators in 
radiotherapy. Finally, in the expanding field of DDR, it is important to consider 
how DCLK1 is involved in the repair of DNA in cancer and homeostatic injure 
conditions. This will allow clinical and non-clinical researchers and practitioners to 
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avoid possible issues with DCLK1 therapeutics, such as enhanced cancer survival 
and cancer advancement with DCLK1 dependent mitigators during radiotherapy, 
and, more excitingly, inhibition of DCLK1 along with DDR following chemo-
therapy or radiotherapy in cancers will lead the way to develop novel strategies for 
the effective treatment of cancer.
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